Streetbeat News

Price Targets

VALE

A whale investor has taken a bullish stance on Vale (NYSE:VALE), with 73% of detected trades showing bullish expectations. Whales have been targeting a price range of $12.0 to $16.0 for Vale over the last 3 months. RBC Capital upgraded its action to Outperform with a price target of $15.

Portfolio Pulse from Benzinga Insights

June 07, 2023 | 7:04 pm

ELF

LRLCY

DA Davidson analyst Linda Bolton Weiser reiterated a Buy rating on E.L.F. Beauty (NYSE:ELF) and raised the price target to $124 from $121, citing the company's rising social media influence. ELF's Facebook and Instagram followers increased by 12%, while competitor L'Oreal (OTC:LRLCY) failed to grow its followers. However, the analyst cautioned about ELF's reliance on a limited number of retailers and international economic uncertainties.

Portfolio Pulse from Nabaparna Bhattacharya

June 07, 2023 | 6:50 pm

AMZN

GOOG

GOOGL

NVDA

SNOW

Piper Sandler analyst Thomas Champion maintains an Overweight rating on Amazon.com Inc (NASDAQ:AMZN) and raises the price target from $130 to $150. He predicts that Amazon's proprietary silicon strategy may boost AWS growth and performance. The recent Nvidia Corp (NASDAQ:NVDA) print indicates a historic demand shift towards AI computing, with Alphabet Inc (NASDAQ:GOOG) (NASDAQ:GOOGL) Google searches and Reddit data showing strong interest in AWS AI offerings.

Portfolio Pulse from Anusuya Lahiri

June 07, 2023 | 6:46 pm

CIEN

Needham analyst Alex Henderson reiterated a Buy rating on Ciena Corporation (NYSE:CIEN) and lowered the price target to $60 from $70. The company's strong demand and improving supply chain are expected to result in double-digit growth, GM expansion, and significant operating leverage. Ciena is also expected to execute large buybacks, providing additional support for its stock.

Portfolio Pulse from Nabaparna Bhattacharya

June 07, 2023 | 6:41 pm

AZN

IONS

Piper Sandler assumes coverage of Ionis Pharmaceuticals with an Overweight rating and a price target of $58, citing a strategic pivot towards commercializing select assets. The analyst sees three key late-stage value drivers: eplontersen, olezarsen, and donidalorsen. Eplontersen is co-commercialized with AstraZeneca in the U.S.

Portfolio Pulse from Vandana Singh

June 07, 2023 | 6:26 pm

AZN

A whale investor has taken a bearish stance on AstraZeneca (NASDAQ:AZN), with 61% of detected trades having bearish expectations. Whales have been targeting a price range of $65.0 to $77.5 for AstraZeneca over the last 3 months. Argus Research maintains a Buy rating on AstraZeneca with a price target of $80.

Portfolio Pulse from Benzinga Insights

June 07, 2023 | 6:17 pm

PNW

In the last 3 months, 9 analysts have offered 12-month price targets for Pinnacle West Capital (NYSE:PNW), with an average price target of $77.33. The average price target has increased by 3.26% over the past month.

Portfolio Pulse from Benzinga Insights

June 07, 2023 | 6:01 pm

COYA

EF Hutton analyst Elemer Piros reiterates a Buy rating on Coya Therapeutics (NASDAQ:COYA) and maintains a $28 price target.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2023 | 5:45 pm

MCD

Benzinga's options scanner detected over 10 options trades for McDonald's (NYSE:MCD) totaling $367,579. Whales have been targeting a price range of $265 to $290 for McDonald's over the last 3 months. TD Cowen maintains an Outperform rating on McDonald's with a price target of $326.

Portfolio Pulse from Benzinga Insights

June 07, 2023 | 5:32 pm

PLAY

Dave & Buster's Entertainment reported better-than-expected Q1 EPS results, leading to multiple firms raising their respective price targets for the company.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2023 | 5:18 pm